All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Is CAR-T an option for patients with MDS?
During the European School of Haematology (ESH) 2nd Translational Research Conference: Erythropoiesis Control and Ineffective Erythropoiesis - From Bench to Bedside, the MDS Hub spoke to Rafael Bejar, UC San Diego, San Diego, US. We asked, Is CAR-T an option for patients with MDS?
Is CAR-T an option for patients with MDS?
Chimeric antigen receptor (CAR) T-cell therapy involves an engineered protein that gives T cells the ability to target specific antigens on tumor cells. Bejar believes that CAR T-cells could provide a promising therapy for MDS in the future.
Related articles
Newsletter
Subscribe to get the best content related to MDS delivered to your inbox